IMRX IMMUNEERING CORP

Immuneering to Provide Updates from Phase 2a Clinical Trial of IMM-1-104 in First-Line Pancreatic Cancer Patients on Tuesday, June 17, 2025

Immuneering to Provide Updates from Phase 2a Clinical Trial of IMM-1-104 in First-Line Pancreatic Cancer Patients on Tuesday, June 17, 2025

CAMBRIDGE, Mass., June 16, 2025 (GLOBE NEWSWIRE) -- Immuneering Corporation (Nasdaq: IMRX), a clinical-stage oncology company outpacing cancer to help patients outlive their disease, today announced that it will host a conference call and live webcast at 8:00 am ET on June 17, 2025. The company is excited to provide updates from its ongoing Phase 2a clinical trial of IMM-1-104 in first-line pancreatic cancer patients.

The conference call will be webcast live and archived in the Investor Relations section of Immuneering’s website at .

About Immuneering Corporation

Immuneering is a clinical-stage oncology company outpacing cancer to help patients outlive their disease. The Company’s lead product candidate, IMM-1-104, is an oral, once-daily deep cyclic inhibitor of MEK designed to improve durability and tolerability, and expand indications to include MAPK pathway-driven tumors such as most pancreatic cancers. IMM-1-104 is currently in a Phase 2a trial in patients with advanced solid tumors including pancreatic cancer. The Company’s development pipeline also includes early-stage programs. For more information, please visit

Media Contact: 

Jenna Urban 

Investor Contact: 

Laurence Watts 

619-916-7620 



EN
16/06/2025

Underlying

IMRXIMMUNEERING CORP

To request access to management, click here to engage with our
partner Phoenix-IR's CorporateAccessNetwork.com

Reports on IMMUNEERING CORP

 PRESS RELEASE
Free
IMRX IMMUNEERING COR...

Immuneering to Provide Updates from Phase 2a Clinical Trial of IMM-1-1...

Immuneering to Provide Updates from Phase 2a Clinical Trial of IMM-1-104 in First-Line Pancreatic Cancer Patients on Tuesday, June 17, 2025 CAMBRIDGE, Mass., June 16, 2025 (GLOBE NEWSWIRE) -- Immuneering Corporation (Nasdaq: IMRX), a clinical-stage oncology company outpacing cancer to help patients outlive their disease, today announced that it will host a conference call and live webcast at 8:00 am ET on June 17, 2025. The company is excited to provide updates from its ongoing Phase 2a clinical trial of IMM-1-104 in first-line pancreatic cancer patients. The conference call will be webc...

8h / 19m 1 EN
 PRESS RELEASE
Free
IMRX IMMUNEERING COR...

Immuneering to Present at the Jefferies Global Healthcare Conference

Immuneering to Present at the Jefferies Global Healthcare Conference CAMBRIDGE, Mass., May 29, 2025 (GLOBE NEWSWIRE) -- Immuneering Corporation (Nasdaq: IMRX), a clinical-stage oncology company seeking to develop and commercialize more effective and better tolerated therapies for cancer patients, today announced that management will present at the Jefferies Global Healthcare Conference, which is taking place at the Marriott Marquis in New York City from June 4-5, 2025, to discuss the company’s pipeline, platform, and business strategy. Participating will be Ben Zeskind, Chief Executive Of...

May 29, 2025 1 EN
 PRESS RELEASE
Free
IMRX IMMUNEERING COR...

Immuneering Reports First Quarter 2025 Financial Results and Provides ...

Immuneering Reports First Quarter 2025 Financial Results and Provides Business Updates - Progression-free survival data from more than 30 patients with first line pancreatic cancer in the ongoing Phase 2a trial of IMM-1-104 trial planned for announcement in 2Q’25 - - Reported positive data from the Company’s ongoing Phase 2a trial of lead program IMM-1-104, including encouraging responses in combination with chemotherapy in first-line pancreatic cancer, and as monotherapy in second-line pancreatic cancer - - Announced clinical trial supply agreement with Regeneron Pharmaceuticals to evalu...

May 5, 2025 1 EN
 PRESS RELEASE
Free
IMRX IMMUNEERING COR...

Immuneering to Present at the 24th Annual Needham Virtual Healthcare C...

Immuneering to Present at the 24th Annual Needham Virtual Healthcare Conference CAMBRIDGE, Mass., April 02, 2025 (GLOBE NEWSWIRE) -- Immuneering Corporation (Nasdaq: IMRX), a clinical-stage oncology company seeking to develop and commercialize more effective and better tolerated therapies for cancer patients, today announced that management will present at the 24th Annual Needham Virtual Healthcare Conference, which is taking place from April 7-10, 2025, to discuss the company’s pipeline, platform, and business strategy. Participating will be Ben Zeskind, Chief Executive Officer, Brett Ha...

April 2, 2025 1 EN
 PRESS RELEASE
Free
IMRX IMMUNEERING COR...

Immuneering Corporation Announces Grant of Inducement Award

Immuneering Corporation Announces Grant of Inducement Award CAMBRIDGE, Mass., March 21, 2025 (GLOBE NEWSWIRE) -- Immuneering Corporation (Nasdaq: IMRX), a clinical-stage oncology company seeking to develop and commercialize more effective and better tolerated therapies for cancer patients, previously announced on March 20, 2025, that Igor Matushansky, M.D., Ph.D., was named Chief Medical Officer of the Company. In connection with the commencement of Dr. Matushanky’s employment, on March 21, 2025, Dr. Matushanky was granted an option to purchase 118,000 shares of the Company’s Class A comm...

March 21, 2025 1 EN

ResearchPool Subscriptions

Get the most out of your insights

Get in touch